版本:
中国

BRIEF-Genmab announces preliminary cervical cancer data from tisotumab vedotin phase I/II study

June 16 Genmab A/S

* Genmab announces preliminary cervical cancer data from tisotumab vedotin phase i/ii study

* Genmab says considering plans for further clinical development of tisotumab vedotin in cervical cancer

* Genmab - conjunctivitis was identified as a tisotumab vedotin specific toxicity, which led to introducing of prophylactic management

* Genmab - in cervical cancer cohort, 15 patients experienced one or more grade 3 adverse events

* Genmab - safety profile of tisotumab vedotin consistent with known mmae based antibody-drug conjugates including peripheral neuropathy and neutropenia Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐